About pharvaris - PHVS
Pharvaris NV is a clinical-stage company, which engages in bringing oral bradykinin B2-receptor antagonists to patients. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Johannes Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
PHVS At a Glance
Pharvaris NV
Emmy Noetherweg 2
Leiden, Zuid-Holland 2333 BK
| Phone | 31-71-203-64-10 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -109,057,609.97 | |
| Sector | Health Technology | Employees | 82 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
PHVS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.457 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.172 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.00 |
PHVS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,329,970.853 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PHVS Liquidity
| Current Ratio | 27.245 |
| Quick Ratio | 27.245 |
| Cash Ratio | 26.792 |
PHVS Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -35.212 |
| Return on Equity | -37.378 |
| Return on Total Capital | -25.691 |
| Return on Invested Capital | -37.358 |
PHVS Capital Structure
| Total Debt to Total Equity | 0.062 |
| Total Debt to Total Capital | 0.062 |
| Total Debt to Total Assets | 0.06 |
| Long-Term Debt to Equity | 0.011 |
| Long-Term Debt to Total Capital | 0.011 |